Eli Lilly and Company $LLY Stake Boosted by Tanager Wealth Management LLP

Tanager Wealth Management LLP lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 84.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,128 shares of the company’s stock after purchasing an additional 518 shares during the period. Tanager Wealth Management LLP’s holdings in Eli Lilly and Company were worth $1,305,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Maseco LLP grew its holdings in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after acquiring an additional 28 shares during the period. Marshall & Sterling Wealth Advisors Inc. raised its position in Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter worth $42,000. Caitlin John LLC purchased a new position in Eli Lilly and Company in the second quarter worth $64,000. Finally, IMG Wealth Management Inc. lifted its holdings in Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after acquiring an additional 50 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Guggenheim increased their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a report on Friday, September 18th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 15th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,314.93.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,285.61 on Wednesday. Eli Lilly and Company has a 1-year low of $793.82 and a 1-year high of $1,311.75. The company has a market capitalization of $1.21 trillion, a P/E ratio of 43.14, a PEG ratio of 1.65 and a beta of 0.46. The business has a 50 day moving average price of $1,181.79 and a 200 day moving average price of $1,114.16. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts expect that Eli Lilly and Company will post 33.56 EPS for the current fiscal year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs raised its price target to $1,413 from $1,371 and reiterated a Buy rating. The firm reportedly expects Lilly to exceed third-quarter earnings estimates and raise its outlook, supported by stronger international Mounjaro growth and increased Zepbound volumes through the Medicare GLP-1 Bridge program. Goldman Sachs raises Eli Lilly price target
• Positive Sentiment: Demand for Mounjaro and Zepbound remains the primary investment catalyst. Lilly’s GLP-1 portfolio is driving rapid revenue and earnings growth, while its oral obesity treatment Foundayo is approaching potential European approval and could support further market-share gains. Lilly valuation and GLP-1 growth ahead of earnings
• Positive Sentiment: Omvoh produced encouraging Phase 3 data in pediatric ulcerative colitis. Among Week 12 responders, 50% achieved clinical remission at Week 52, while 71.2% achieved symptomatic remission. Lilly plans to submit the results to regulators, potentially expanding Omvoh’s inflammatory bowel disease market. Lilly Omvoh pediatric ulcerative colitis trial
• Neutral Sentiment: Lilly reports third-quarter results on October 29. Expectations for another strong quarter are supporting momentum, but the elevated valuation leaves the stock sensitive to any earnings or guidance disappointment. Eli Lilly reaches high ahead of earnings
• Negative Sentiment: Investors continue to weigh risks from Lilly’s premium valuation, potential pricing competition with Novo Nordisk and heavy reliance on its obesity and diabetes franchise. A Pennsylvania lawsuit also alleges insulin price inflation, creating possible legal and reputational risks, although no outcome has been determined. Lilly insulin pricing lawsuit

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.